Venous thromboembolism following minimally invasive surgery among women with endometrial cancer

Freeman, A.H.; Barrie, A.; Lyon, Liisa; Littell, Ramey D.; Garcia, Christine; Conell, Carol; Powell, C. Bethan

doi:10.1016/j.ygyno.2016.06.002

Cited by 42 publications

(32 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reasons for exclusion are in Figure . Eleven articles reported the incidence of VTE at 3 months (primary outcome) following surgery . However, we were able to find 13 articles that reported the incidence of VTE at 1 month from surgery (secondary outcome).…”

Section: Resultsmentioning

confidence: 93%

Incidence of delayed venous thromboembolic events in patients undergoing abdominal and pelvic surgery for cancer: a systematic review and meta‐analysis

Serrano

Parpia

Valencia

et al. 2019

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background: Incidence of venous thromboembolism (VTE) following discharge for abdominal cancer surgery is uncertain. Methods: We searched MEDLINE and Embase for studies evaluating the incidence of VTE at 3 months from surgery. Studies indicating use of post-hospital VTE prophylaxis were excluded. Two independent reviewers performed study selection, data abstraction and risk of bias. Random-effects model was used to estimate pooled incidence, and weights were estimated using inverse variance method. Statistical heterogeneity was explored via subgroup analysis. Results: Of 4215 abstracts retrieved, 11 reported the incidence of VTE at 3 months. There were three randomized trials (n = 520), one prospective cohort study (n = 284) and seven retrospective cohort studies (n = 65 308). VTE incidence among prospective studies was 9.6% (95% confidence interval (CI) 2.9-16.4), while for retrospective studies was 2.2% (95% CI 1.4-3.0). Heterogeneity was high (I 2 = 92% and 81%, respectively). The incidence of symptomatic VTE was 1.3% (95% CI 0.4-2.3) for prospective studies. VTE was diagnosed by screening venography in most of the prospective studies, whereas retrospective studies did not use a screening method. Subgroup analysis based on the type of organ surgery performed explained the heterogeneity. Conclusions: VTE incidence following abdominal cancer surgery varies greatly depending on the study type, with differences largely explained by the method of assessment of VTE. The fact that VTE incidence among retrospective studies was closer to the incidence of symptomatic events (non-screen detected) in the prospective studies, suggests that the screened events were mostly asymptomatic and their clinical significance is unclear.

show abstract

Section: Resultsmentioning

confidence: 93%

Incidence of delayed venous thromboembolic events in patients undergoing abdominal and pelvic surgery for cancer: a systematic review and meta‐analysis

Serrano

Parpia

Valencia

et al. 2019

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…13Y20 Of note, only 1 of these studies included patients receiving EP up to 4 weeks as suggested for consideration by current guidelines, and in that study, only 6.4% of patients received EP. 18 This study was also the only one in which the majority of patients received perioperative prophylactic heparin. The risk of VTE in the minimally invasive surgery population must be weighed against the risk of pharmacologic prophylaxis, which includes bleeding complications, injection site ecchymoses, and thrombocytopenia.…”

mentioning

confidence: 99%

Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer

Kim

Mills

Fehniger

et al. 2017

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

In this study, 30-day and 60-day VTE rates after minimally invasive surgery for endometrial cancer were low. Rates were also similar to those of previous reports in this setting in which the majority of patients did not receive extended VTE prophylaxis. Given the consistent finding that postoperative VTE in this population is rare regardless of prophylaxis use and the variability in practice patterns for VTE prophylaxis, the development of best practice guidelines for EP use specific to this setting is warranted.

show abstract

“…None of the seven studies with overall high-anticoagulation rates of 98 to 100% 26,27,35,39,43,47,49 had an MV-positive transfusion-thrombosis correlation, compared with 3 25,40,41 of 10 (30%) with anticoagulation rates of 0 to 75% or "rare" or "most." 25,29,31,36,38,40,41,[50][51][52] However, three of the high-anticoagulation studies still had UV-positive correlation with transfusion and/or correlation with transfusion volume. 27,39,43 More data are needed to draw a firm conclusion about the effect of anticoagulation rates.…”

Section: Resultsmentioning

confidence: 99%

Thrombosis Risk in Cancer Patients Receiving Red Blood Cell Transfusions

Ramsey

Lindholm

2019

Semin Thromb Hemost

View full text Add to dashboard Cite

Patients with cancer have increased risk of thrombosis and often need red blood cell (RBC) transfusions. However, RBC transfusions may also promote thrombosis because of raised hematocrit and viscosity, storage-related RBC damage, and exposure to thrombogenic mediators from obsolescent RBCs. The authors conducted a literature survey for studies examining whether RBC transfusions were associated with increased risk of venous thromboembolism (VTE) in cancer patients. In perioperative cancer surgery patients with categorical comparisons of any versus no RBC transfusion, increased risk of VTE with RBC transfusion was found in 11 of 31 studies, 5 by univariate correlation only and 6 in multivariate analysis. All six multivariate-positive studies had intermediate overall rates of thrombosis (1.4–6.0%), and three were in urological surgery series. In the larger studies of > 2,000 patients (range: 2,219–44,656), the maximum odds ratio among the multivariate-positive studies was 1.3. Perioperative RBC transfusion volume was more strongly associated with VTE risk, with a positive association in six of seven studies. One large registry-based study of hospitalized cancer patients, not restricted to the perioperative setting, found an adjusted odds ratio of 1.60 (95% confidence interval: 1.53–1.67) for VTE risk in patients receiving RBCs compared with nontransfused patients.

show abstract

Venous thromboembolism following minimally invasive surgery among women with endometrial cancer

Cited by 42 publications

References 22 publications

Incidence of delayed venous thromboembolic events in patients undergoing abdominal and pelvic surgery for cancer: a systematic review and meta‐analysis

Incidence of delayed venous thromboembolic events in patients undergoing abdominal and pelvic surgery for cancer: a systematic review and meta‐analysis

Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer

Thrombosis Risk in Cancer Patients Receiving Red Blood Cell Transfusions

Contact Info

Product

Resources

About